 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...224225226227228229230231232233234235236» |
- | New P2 trial, Surgery: Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") (clinicaltrials.gov) - Nov 13, 2012
P2, N=100, Recruiting, Sponsor: Medical College of Wisconsin
- ||||| Neulasta (pegfilgrastim) / Roche
Enrollment closed, Metastases: PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study (clinicaltrials.gov) - Nov 13, 2012
P3, N=847, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting
- ||||||| Litx (talaporfin) / Light Sciences Oncology
Trial completion: Phase 3 Trial of Litx (clinicaltrials.gov) - Nov 13, 2012
P3, N=483, Completed, Sponsor: Light Sciences Oncology
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Recentin (cediranib) / AstraZeneca
Enrollment change: Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers (clinicaltrials.gov) - Nov 7, 2012
P2, N=36, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=25 --> 36
- |||||| onartuzumab (RG3638) / Roche
Enrollment open, Combination therapy, Metastases: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer (clinicaltrials.gov) - Nov 4, 2012
P3, N=800, Recruiting, Sponsor: Hoffmann-La Roche
N=25 --> 36 Not yet recruiting --> Recruiting
- Trial termination: Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma (clinicaltrials.gov) - Oct 31, 2012
P2, N=2, Terminated, Sponsor: University of Texas Southwestern Medical Center
Not yet recruiting --> Recruiting Recruiting --> Terminated; Drug shortage
- Enrollment change: Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma (clinicaltrials.gov) - Oct 31, 2012
P2, N=2, Terminated, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Terminated; Drug shortage N=25 --> 2
- ||| Avastin (bevacizumab) / Roche
Enrollment change, Metastases: A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin (clinicaltrials.gov) - Oct 31, 2012
P2, N=76, Completed, Sponsor: Hoffmann-La Roche
N=25 --> 2 N=95 --> 76
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment change, Metastases: A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 31, 2012
P1, N=19, Completed, Sponsor: Novartis Pharmaceuticals
N=95 --> 76 N=29 --> 19
- ||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion: Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer (clinicaltrials.gov) - Oct 31, 2012
P2/3, N=426, Completed, Sponsor: Taiho Pharmaceutical Co., Ltd.
N=29 --> 19 Active, not recruiting --> Completed
- Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment change: Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-? Blockers (clinicaltrials.gov) - Oct 30, 2012
P2, N=16, Terminated, Sponsor: Sanofi
Active, not recruiting --> Completed N=250 --> 16
- |||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion, Combination therapy, Metastases: Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 30, 2012
P2, N=107, Completed, Sponsor: Taiho Pharmaceutical Co., Ltd.
N=250 --> 16 Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial: PRIMM: Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer (clinicaltrials.gov) - Oct 24, 2012
P2, N=40, Recruiting, Sponsor: Institut Gustave Roussy
- | 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Biomarker, New P2 trial, Metastases: Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer. (clinicaltrials.gov) - Oct 24, 2012
P2, N=127, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- ensituximab (NEO-102) / ImmunityBio
New P1/2 trial, Combination therapy, Metastases: NPC-1C With Gemcitabine for Advanced Pancreatic Cancer (clinicaltrials.gov) - Oct 24, 2012
P1/2, N=18, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Vectibix (panitumumab) / Amgen
Enrollment open: Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques (clinicaltrials.gov) - Oct 23, 2012
P2, N=80, Recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment open, Metastases: Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours (clinicaltrials.gov) - Oct 22, 2012
P2, N=50, Recruiting, Sponsor: Per Pfeiffer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Metastases: FIRE-3: 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) (clinicaltrials.gov) - Oct 21, 2012
P3, N=568, Active, not recruiting, Sponsor: PD Dr. med. Volker Heinemann
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Neutrexin (trimetrexate) / Pfizer
Enrollment change, Metastases: Combination Chemotherapy in Treating Patients With Advanced Cancer of the Pancreas (clinicaltrials.gov) - Oct 15, 2012
P2, N=21, Completed, Sponsor: University of Southern California
Recruiting --> Active, not recruiting N=33 --> 21
- Neutrexin (trimetrexate) / Pfizer
Trial completion, Metastases: Combination Chemotherapy in Treating Patients With Advanced Cancer of the Pancreas (clinicaltrials.gov) - Oct 15, 2012
P2, N=21, Completed, Sponsor: University of Southern California
N=33 --> 21 Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: BEBYP: Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab (clinicaltrials.gov) - Oct 11, 2012
P3, N=262, Active, not recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: TRIBE: Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 11, 2012
P3, N=509, Completed, Sponsor: Gruppo Oncologico del Nord-Ovest
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment change, Metastases: Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 9, 2012
P1/2, N=65, Completed, Sponsor: Kyowa Hakko Kirin Pharma, Inc.
Recruiting --> Completed N=102 --> 65
- | Vectibix (panitumumab) / Amgen
New P2 trial: Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques (clinicaltrials.gov) - Oct 9, 2012
P2, N=80, Recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion, Metastases: Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 9, 2012
P1/2, N=65, Completed, Sponsor: Kyowa Hakko Kirin Pharma, Inc.
N=102 --> 65 Active, not recruiting --> Completed
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change: A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer (clinicaltrials.gov) - Oct 8, 2012
P2, N=180, Recruiting, Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Active, not recruiting --> Completed N=240 --> 180
- Erbitux (cetuximab) / Eli Lilly
Biomarker, New P2 trial, Metastases: Biomarker Directed Treatment in Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 8, 2012
P2, N=30, Recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
- leucovorin calcium / Generic mfg., temozolomide / Generic mfg.
New P1 trial, Combination therapy: FOLAGLI: Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma (clinicaltrials.gov) - Oct 2, 2012
P1, N=44, Recruiting, Sponsor: Institut Cancerologie de l'Ouest
- Rituxan (rituximab) / Roche
Trial completion: S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - Oct 2, 2012
P2, N=56, Completed, Sponsor: Southwest Oncology Group
N=240 --> 180 Active, not recruiting --> Completed
- | pimasertib (AS703026) / Day One Biopharma
Enrollment change, Metastases: MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Sep 30, 2012
P2, N=16, Completed, Sponsor: EMD Serono
Active, not recruiting --> Completed N=214 --> 16
- | pimasertib (AS703026) / Day One Biopharma
Trial completion, Metastases: MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Sep 30, 2012
P2, N=16, Completed, Sponsor: EMD Serono
N=214 --> 16 Active, not recruiting --> Completed
- ||| Cyramza (ramucirumab) / Eli Lilly
Enrollment closed, Metastases: A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer (clinicaltrials.gov) - Sep 27, 2012
P2, N=166, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Trial termination: Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer (clinicaltrials.gov) - Sep 19, 2012
P2, N=119, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; low accrual
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., cisplatin / Generic mfg.
Trial termination, Surgery, Metastases: Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer (clinicaltrials.gov) - Sep 19, 2012
P3, N=144, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; low accrual Active, not recruiting --> Terminated; low accrual
- Avastin (bevacizumab) / Roche
Enrollment change: Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer (clinicaltrials.gov) - Sep 19, 2012
P2, N=119, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; low accrual N=152 --> 119
- | Trial completion, Metastases: Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 19, 2012
P3, N=86, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=152 --> 119 Active, not recruiting --> Completed
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion, Combination therapy, Metastases: Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 19, 2012
P3, N=430, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P2 trial, Metastases: FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Sep 17, 2012
P2, N=45, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Biomarker, Trial completion, Metastases: Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Sep 17, 2012
P2, N=33, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- dexamethasone / Generic mfg., floxuridine / Generic mfg.
Enrollment closed, Combination therapy: Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver (clinicaltrials.gov) - Sep 16, 2012
P2, N=64, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Trial initiation date: PERIMAX: Perioperative Treatment of Resectable Liver Metastases (clinicaltrials.gov) - Sep 12, 2012
P2, N=0, Withdrawn, Sponsor: University of Regensburg
Recruiting --> Active, not recruiting Initiation date: Mar 2012 --> Sep 2012
- Otrexup (methotrexate) / Halozyme, Rituxan (rituximab) / Roche
Enrollment change: Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma (clinicaltrials.gov) - Sep 11, 2012
P2, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Mar 2012 --> Sep 2012 N=18 --> 28
- GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis
Enrollment open, Tumor cell: Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Sep 9, 2012
P=N/A, N=18, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=18 --> 28 Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Enrollment closed: Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - Sep 6, 2012
P1, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- sunitinib / Generic mfg.
Trial completion, Metastases: FOLFIRI and Sunitinib in Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 6, 2012
P2, N=22, Completed, Sponsor: Central European Society for Anticancer Drug Research
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Avastin (bevacizumab) / Roche, parsatuzumab (RG7414) / Roche
Enrollment closed, Combination therapy, Metastases: A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 5, 2012
P2, N=128, Active, not recruiting, Sponsor: Genentech
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Metastases: CALGB: Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 5, 2012
P3, N=2900, Active, not recruiting, Sponsor: Cancer and Leukemia Group B
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Enrollment change, Combination therapy, Metastases: High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 4, 2012
P2, N=10, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting N=50 --> 10
- oxaliplatin / Generic mfg., irinotecan / Generic mfg., capecitabine / Generic mfg.
New P2 trial: Neoadjuvant Folfirinox Followed by Capecitabine and Limited Field Radiation for Localized Pancreatic Head Adenocarcinoma (clinicaltrials.gov) - Aug 30, 2012
P2, N=30, Recruiting, Sponsor: Medical University of South Carolina
- Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, Metastases: Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 30, 2012
P1, N=17, Completed, Sponsor: Case Comprehensive Cancer Center
N=50 --> 10 Active, not recruiting --> Completed